Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr. Reddy’s Explores Drug Delivery Options For In-House Molecule

This article was originally published in PharmAsia News

Executive Summary

Hyderabad, India-based Dr. Reddy's announced Feb. 8 an agreement with drug delivery firm SkyePharma to conduct a feasibility study of a Dr. Reddy's product utilizing two of the London-based firm's drug delivery systems. Dr. Reddy's will fund the study and pay SkyePharma an up-front fee. SkyePharma was unwilling to share further details on the agreement with PharmAsia News. Indian firms such as Dr. Reddy's are increasingly turning to novel drug delivery systems to strengthen their products' market position (PharmAsia News, Feb. 7, 2008)

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts